Atara Biotherapeutics Files 8-K: Rights, Bylaws, and Financials Updated
Ticker: ATRA · Form: 8-K · Filed: Jun 20, 2024 · CIK: 1604464
| Field | Detail |
|---|---|
| Company | Atara Biotherapeutics, INC. (ATRA) |
| Form Type | 8-K |
| Filed Date | Jun 20, 2024 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-governance, filing, legal-update
Related Tickers: ATRA
TL;DR
ATRA filed an 8-K updating shareholder rights, bylaws, and financials. Keep an eye on governance changes.
AI Summary
On June 20, 2024, Atara Biotherapeutics, Inc. filed an 8-K report detailing material modifications to the rights of its security holders. The filing also includes amendments to its articles of incorporation or bylaws and financial statements and exhibits.
Why It Matters
This filing indicates significant corporate actions by Atara Biotherapeutics, potentially impacting shareholder rights and the company's governance structure.
Risk Assessment
Risk Level: medium — Filings related to modifications of security holder rights and amendments to corporate bylaws can introduce new risks or alter existing ones for investors.
Key Players & Entities
- Atara Biotherapeutics, Inc. (company) — Registrant
- June 20, 2024 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of Incorporation
- 001-36548 (filing_number) — SEC File Number
- 46-0920988 (tax_id) — IRS Employer Identification No.
- 2380 Conejo Spectrum St, Suite 200 (address) — Principal Executive Offices
- Thousand Oaks, CA 91320 (location) — Principal Executive Offices City, State, Zip
FAQ
What specific material modifications were made to the rights of Atara Biotherapeutics' security holders?
The filing indicates material modifications to the rights of security holders, but the specific details of these modifications are not elaborated upon in the provided text, requiring a review of the full document.
What are the key amendments to Atara Biotherapeutics' articles of incorporation or bylaws?
The filing states that amendments to the articles of incorporation or bylaws have been made, but the specific nature of these amendments is not detailed in the provided excerpt.
What is the significance of filing financial statements and exhibits with this 8-K?
The inclusion of financial statements and exhibits suggests that these documents are relevant to the other reported items, such as the modifications to security holder rights or bylaw amendments, and provide supporting financial information.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing occurred on June 20, 2024.
Where are Atara Biotherapeutics' principal executive offices located?
Atara Biotherapeutics, Inc.'s principal executive offices are located at 2380 Conejo Spectrum St, Suite 200, Thousand Oaks, CA 91320.
Filing Stats: 808 words · 3 min read · ~3 pages · Grade level 10.7 · Accepted 2024-06-20 17:04:31
Key Financial Figures
- $0.0001 — ich Registered Common Stock, par value $0.0001 per share ATRA The Nasdaq Stock Mar
Filing Documents
- d843613d8k.htm (8-K) — 28KB
- d843613dex31.htm (EX-3.1) — 7KB
- 0001193125-24-164554.txt ( ) — 162KB
- atra-20240620.xsd (EX-101.SCH) — 3KB
- atra-20240620_lab.xml (EX-101.LAB) — 18KB
- atra-20240620_pre.xml (EX-101.PRE) — 11KB
- d843613d8k_htm.xml (XML) — 4KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 3.1 Certificate of Amendment to the Amended and Restated Certificate of Incorporation of Atara Biotherapeutics, Inc. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. Atara Biotherapeutics, Inc. By: /s/ Amar Murugan Amar Murugan Executive Vice President and Chief Legal Officer Date: June 20, 2024